blog
Last updated: 2015-08-13

Ankle Joint Arthritis: Stem Cell Regenerative Medicine Therapy

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Ankle Joint Arthritis: Stem Cell Regenerative Medicine Therapy

Ankle Arthritis: Autologous Stem Cell Regenerative Therapy

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

Regenerative Medicine Case Study

  • July 3, 2019

Ankle joint arthritis, like hip and knee osteoarthritis, results from articular cartilage degeneration and inflammation. Regenerative medicine approaches using autologous stem cells offer potential therapeutic option.

Clinical Presentation

Patient presented with ankle pain during ambulation, with pain persisting even at rest. MRI imaging revealed severe inflammation of the talus, the bone central to ankle mobility.

Treatment Approach

Therapy: Autologous adipose tissue-derived mesenchymal stem cells (100 million cells) combined with platelet-rich plasma (PRP)

Clinical Outcomes

One-Month Follow-Up:

  • Reduction in inflammatory response at treatment site
  • Pain resolution at rest
  • Persistent mild discomfort with weight-bearing activities
  • Continued improvement expected with time

Mechanism of Action

Mesenchymal stem cells promote regeneration of damaged articular cartilage and modulate inflammatory response, supporting tissue healing and functional restoration.

Data Source

Iwata Clinic regenerative medicine case series

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

Figure 1Figure 1

Related Reading

IL-21 NK Cells Demonstrate Anti-Tumor Potential Against Glioblastoma

IL-21-expressing NK cells demonstrate sustained anti-tumor activity against glioblastoma stem cell-like cells (GSCs). Both in vitro and in vivo experiments confirm this effect, bringing new breakthroughs in glioblastoma treatment.

2026-03-17

AI Meets Cancer: Personalized Bladder Cancer Treatment

[The New Integration of AI and Bladder Cancer Treatment] AI technology and machine learning are making bladder cancer treatment more personalized, helping doctors predict patient responses to chemotherapy. By utilizing whole-slide tumor imaging and gene expression analysis, th...

2026-02-04

新生抗原是什麼?

之前我們寫了一篇關於日本免疫治療的趨勢後,有幾位跟我們聯繫,是否能夠更加詳盡的介紹樹突細胞。從免疫檢查哨抑制劑(Nivolumab等)的開發以及機制中能夠發現,CTL這種特殊的T淋巴球是相當重要的。因此藉由樹突細胞疫苗讓CTL增加,是對於癌症治療的方法之一。另外,單單的樹突細胞疫苗必須要認識癌細胞才能給予CTL指令,我

2026-08-19

聯合免疫療法有效縮小轉移性腸癌

【創新免疫療法縮小多種轉移性胃腸道癌症】全新形式的腫瘤浸潤淋巴細胞(TIL)療法在轉移性胃腸道癌症患者中顯示出顯著的治療效果,為癌症患者帶來新希望。這種個性化癌症免疫療法提升了腫瘤縮小率,未來有望應用於多種實體瘤的治療。

2025-11-14